CD68 and melanoma: In patients with malignant melanoma, we found shorter PFS related to FoxP3 nuclear positivity (17.0 vs. 4.5 months, p = 0.048, HR 3.04, 95% CI 0.95–9.71) (Figure 2A) and CD68 positivity (15.0 vs. 4.1 months, p = 0.034, HR 3.21, 95% CI 1.02–10.1).